T ransforming growth factor-b (TGF-b) is a pleiotropic factor. It regulates many aspects of T-cell biology including thymocyte development, T cell differentiation and effector T cell function.
1 Previous work has shown that the loss of TGF-b signaling in the T-cell lineage leads to severe lymphoproliferative autoimmunity. 2, 3 Until now, it has been unclear to what extent the autoimmunity observed in those mice is driven by TGFunresponsive conventional T cells, as TGF-is also crucial for the maintenance and function of regulatory T cells (Treg) . A recent study published in Nature Immunology revealed a novel role of TGF-b signaling in non-regulatory naive T cells. It was found that TGF-b controls lymphopenia-driven T-cell proliferation in neonatal mice, thereby preventing the development of autoimmunity. 4 Zhang and Bevan made this discovery by comparing two animal models in which type II TGF-b receptor (TGF-bRII) was ablated in T cells at different developmental stages. In the previous study, researchers specifically deleted TGF-bRII using Cre recombinase driven by the promoter of CD4 (Tgfbr2 f/f CD4-Cre). In this model system, TGF-bRII is deleted in T cells by the time they emerge from the thymus. As a result, these mice show severe autoimmunity and early mortality (3-5 weeks). The autoimmune phenotype observed in these mice cannot be rescued by transferring wild-type T reg cells or by reconstituting them with mixed bone marrow from wild-type and Tgfbr2 f/f CD4-Cre mice. 2, 3 Together, these findings show that the onset of autoimmunity in the Tgfbr2 f/f CD4-Cre model is at least partially due to the self-reactivity of TGF-b unresponsive conventional T cells. Zhang and Bevan studied a different TGF-bRII conditional deletion model, in which the expression of Cre is driven by the distal promoter of the kinase Lck (Tgfbr2 f/f dLck-Cre). In this model, the T cellspecific deletion of TGF-bRII begins in mature T cells and is much slower. Although TGF-bRII is almost completely deleted in T cells in adult mice (7-9 weeks), the expression of TGF-bRII is unaffected in neonates (day 4). The delayed deletion ofTGF-bRIIledtoadifferentphenotype:Tgfbr2 f/f dLck-Cre showed no signs of autoimmune lesions and survived for up to a year. 3, 4 Using this model, Zhang and Bevan examined why the expression of TGF-bRII on T cells during neonatal development protects the host from autoimmunity later in life. In neonatal mice, the lymphopenic environment allows naive T cells to undergo proliferation driven by weak engagement of the T-cell receptor (TCR) with self ligands and homeostatic cytokines interleukin 7 (IL-7) and IL-15. 5 Zhang and Bevan found that TGF-b signaling in naive T cells was essential to restrain this lymphopenia-driven proliferation in neonatal animals. TGF-bRII-deficient naive T cells (from Tgfbr2 f/f dLck-Cre mice) proliferated rapidly upon transfer to Rag1 2/2 or sublethally irradiated wild-type hosts, demonstrating the critical role of TGF-b in regulating homeostatic proliferation in both chronic and acute lymphopenic conditions, respectively. The lack of TGF-b signaling also resulted in an effector phenotype characterized by the increased expression of KLRG1, granzyme B and interferon-c. The hyperproliferative effector phenotype of TGF-bRII-deficient T cells in Rag1 2/2 recipients was associated with autoimmunity, as demonstrated by T-cell organ infiltration and weight loss.
The enhanced proliferative capacity of TGF-b-unresponsive T cells does not appear to be caused by commensal bacteria. Commensal flora generates antigens and inflammatory signals, which contribute to rapid T-cell expansion and autoimmunity in the host. 6 Loss of commensal bacteria upon antibiotic treatment significantly inhibits the lymphopenia-driven proliferation of wildtype T cells; but fails to control the hyperproliferation of TGF-bRII-deficient T cells. Pro-inflammatory cytokines, such as interferon-c, IL-6, tumor-necrosis factor, IL-1b and IL-18, did not enhance the proliferation of TGF-b-unresponsive T cells, and interferon-a and IL-12 even reduced the proliferative advantage of TGF-bRII-deficient T cells over wild-type T cells. These results suggest that TGF-b signaling prevents T-cell proliferation induced by weak TCR signals, but does not affect proliferation induced by foreign antigens or pro-inflammatory cytokines.
The most important finding of this study is related to the role of TGF-b signaling in controlling the T-cell response to tonic 'tickling'. Despite these findings, this study still may not fully explain the severe autoimmune phenotype observed in the Tgfbr2 f/f CD4-Cre model. First, the extent to which the loss of T reg cells in the periphery contributes to the onset of autoimmunity remains unresolved. Unfortunately, TGF-bRII is not deleted in most peripheral T reg cells in the Tgfbr2 f/f dLck-Cre model. Although the transfer experiments suggest that factors other than T reg cells caused the autoimmunity observed in the Tgfbr2 f/f CD4-Cre model, it is possible that the loss of T reg cells enhances the severity of the disease. Second, because CD4-Cre is expressed before thymic negative selection, the loss of TGF-b signaling may alter the Tcell repertoire. Finally, it should also be noted that the development of NKT cells is abrogated in Tgfbr2 f/f CD4-Cre mice. 7 Whether this population plays a role in preventing autoimmunity, however, remains unknown.
In summary, Zhang and Bevan's work demonstrates an inhibitory role for TGF-b signaling in naive T cells during homeostatic proliferation in lymphopenic conditions. Moreover, the dampening effect of TGF-b signaling on T-cell activation in response to weak but not strong TCR stimuli provides valuable insight to understand thymocyte development, T cell maintenance and peripheral tolerance. 
